Short Bowel Syndrome Market

Short Bowel Syndrome Market

Growth Factors of Short Bowel Syndrome Market

The short bowel syndrome market size was valued at USD 1.01 billion in 2023, and the market is now projected to grow from USD 1.15 billion in 2024 to USD 3.36 billion by 2032, exhibiting a CAGR of 14.3% during the forecast period of 2023-2030.

The COVID-19 pandemic created significant challenges on the operative elective surgeries as curbing coronavirus outbreak was prioritized over the surgeries that were not life-threatening unlike COVID. Therefore a huge decline in the elective procedures, operative dental procedures, orthopedic surgeries as well as emergency room visits in the hospitals and operation theatres were on a hold for a significant amount of period that caused an immense downfall in terms of number of post-operative surgeries during the pandemic period, impeding the rise of medical devices market growth.

GLP-2 Drugs' increasing penetration for SBS intestinal failure (SBS-IF) promoting short bowel syndrome market growth. A uncommon disorder called SBS-IF is brought on by short bowel syndrome in patients. Parenteral support must be administered more frequently to patients with this illness. Typically, this medication is given five days a week on average. But continuous parenteral support use is impeding the patient's everyday activities, raising the hospitalization rate, and causing problems related to this therapy, which is driving the market uptake of GLP-2-based medications. Additionally, it is anticipated that during the forecast period, developed countries will see a rise in the penetration of GLP-2 medications. This is because pipeline candidates have a number of advantages, including decreased hospitalization rates and better dosing frequency.

Change the treatment of SBS from total parenteral nutrition to GLP-2drugs will promote market growth. The market has seen a preference for GLP-2 medications over Total Parenteral Nutrition (TPN) in recent years for the treatment of the illness. This is because using parenteral nutrition therapy over an extended period of time might lead to a number of problems. Sepsis from the catheter and problems with the liver and kidneys are risk factors for whole parenteral feeding. As a result, novel medications that help lower the need for parenteral support generally being used to treat this syndrome.

Comprehensive Short Bowel Syndrome Market

The short bowel syndrome market and pharmaceutical industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by types and by distribution channel. The types segmentation includes, GLP-2, Growth Hormone, Glutamine, and Others, while By Distribution Channel segmentation include Hospital Pharmacies and Online & Retail Pharmacies.

The North America region lead the short bowel syndrome market by benefitting a market size of USD 0.75 billion in 2023 due to a sizable patient population using cutting-edge medications and needing innovative therapeutic approaches prolonged use of licensed medications to treat patients in both adult and pediatric settings, as well as a large number of pipeline items.

The prominent players in the market play a crucial role in the pharmaceutical industry assuring industrial prospectus growth and setting market standards. These key industry players include, VectivBio AG (Switzerland), Hanmi Pharm Co., Ltd. (South Korea), Takeda Pharmaceutical Company Limited (Japan), OxThera (Sweden), Zealand Pharma A/S (Denmark), 9 Meters Biopharma, Inc. (U.S.), and Nestlé Health Science (Switzerland) these market players provide a level-playing competitive environment across the globe.

In June 2022, one of the major industry player, has introduced its promising findings of Vurolenatide's phase 2 clinical trial in the treatment of this syndrome were revealed by 9 Meters Biopharma, Inc.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 14.3% from 2024-2032

Unit Value (USD billion)

Segmentation By Type

- GLP-2

- Growth Hormone

- Glutamine

- Others

By Distribution Channel

- Hospital Pharmacies

- Online & Retail Pharmacies

By Geography

- North America (By Type, By Distribution Channel, By Country)

• U.S.
• Canada

- Europe (By Type, By Distribution Channel, By Country/Sub-Region)

• Germany
• U.K
• France
• Italy
• Russia
• Rest of Europe

- Asia Pacific (By Type, By Distribution Channel, By Country/Sub-Region)

• India
• China
• Japan
• Australia
• Southeast Asia
• South Korea
• Rest of Asia Pacific

- Latin America (By Type, By Distribution Channel, By Country/Sub-Region)

• Brazil
• Mexico
• Argentina
• Colombia
• Rest of Latin America

- Middle East & Africa (By Type, By Distribution Channel, By Country/Sub-Region)

• Turkey
• Saudi Arabia
• UAE
• Rest of Middle East & Africa